Central core disease


Central core disease, also known as central core myopathy, is an autosomal dominantly inherited muscle disorder present from birth that negatively affects the skeletal muscles. It was first described by Shy and Magee in 1956. It is characterized by the appearance of the myofibril under the microscope.

Signs and symptoms

The symptoms of CCD are variable, but usually involve hypotonia at birth, mild delay in child development, weakness of the facial muscles, and skeletal malformations such as scoliosis and hip dislocation.
CCD is usually diagnosed in infancy or childhood, but some patients remain asymptomatic until adulthood to middle age. While generally not progressive, there appears to be a growing number of people who do experience a slow clinically significant progression of symptomatology. These cases may be due to the large number of mutations of ryanodine receptor malfunction, and with continued research may be found to be clinical variants.

Pathophysiology

Central core disease is inherited in an autosomal dominant fashion. Most cases have demonstrable mutations in the ryanodine receptor type 1 gene, which are often de novo. People with CCD are at increased risk for developing malignant hyperthermia when receiving general anesthesia.

Diagnosis

The diagnosis is made based on the combination of typical symptoms and the appearance on biopsy from muscle. The name derives from the typical appearance of the biopsy on light microscopy, where the muscle cells have cores that are devoid of mitochondria and specific enzymes.
Respiratory insufficiency develops in a small proportion of cases. Creatine kinase tend to be normal and electromyography shows short duration, short amplitude motor unit action potentials.

Treatment

There is no specific treatment but triggering anesthetics are avoided and relatives are screened for RYR1 mutations as these may make them susceptible to MH.